Thus, by reducing demand on beta cells to secrete insulin as well as reducing glucotoxicity, SGLT2 inhibitors theoretically could reduce the rate of progression of T2DM [34]–[37]. Here, SLC5A2 is linked to type 2 diabetes mellitus.